150 related articles for article (PubMed ID: 12187071)
1. DNA aneuploidy in relation to the combination of analysis of estrogen receptor, progesterone receptor, p53 protein and epidermal growth factor receptor in 498 breast cancers.
Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
Oncology; 2002; 63(1):48-55. PubMed ID: 12187071
[TBL] [Abstract][Full Text] [Related]
2. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
4. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
[TBL] [Abstract][Full Text] [Related]
5. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators.
Levesque MA; Clark GM; Yu H; Diamandis EP
Br J Cancer; 1995 Sep; 72(3):720-7. PubMed ID: 7545416
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the combination of biological parameters in breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Surg Today; 2003; 33(2):151-4. PubMed ID: 12616383
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
8. Histological classification of invasive ductal carcinoma and the biological parameters in breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Breast Cancer; 2003; 10(2):149-52. PubMed ID: 12736568
[TBL] [Abstract][Full Text] [Related]
9. Cytological evaluation of biological prognostic markers from primary breast carcinomas.
Makris A; Allred DC; Powles TJ; Dowsett M; Fernando IN; Trott PA; Ashley SE; Ormerod MG; Titley JC; Osborne CK
Breast Cancer Res Treat; 1997 May; 44(1):65-74. PubMed ID: 9164679
[TBL] [Abstract][Full Text] [Related]
10. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
11. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
[TBL] [Abstract][Full Text] [Related]
12. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
13. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
14. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
16. Relationship between low estrogen receptor values and other prognostic factors in primary breast tumors.
Gaffney EV; Halpin DP; Blakemore WS
Surgery; 1995 Mar; 117(3):241-6. PubMed ID: 7878527
[TBL] [Abstract][Full Text] [Related]
17. Regional heterogeneity in breast carcinoma: thymidine labelling index, steroid hormone receptors, DNA ploidy.
Meyer JS; Wittliff JL
Int J Cancer; 1991 Jan; 47(2):213-20. PubMed ID: 1988366
[TBL] [Abstract][Full Text] [Related]
18. A new look at the prognostic value of the estrogen, progesterone and epidermal growth factor receptors in breast cancer tissue.
Skasko E; Paszko Z; Mazur S
Neoplasma; 2005; 52(1):10-7. PubMed ID: 15739020
[TBL] [Abstract][Full Text] [Related]
19. In vivo effect induced by interferon beta on steroid receptor status, cell kinetics and DNA ploidy in operable breast cancer patients.
Di Martino L; Demontis B; Saccani Iotti G; Murenu G
Anticancer Res; 1995; 15(2):537-41. PubMed ID: 7763036
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers.
Koenders PG; Beex LV; Geurts-Moespot A; Heuvel JJ; Kienhuis CB; Benraad TJ
Cancer Res; 1991 Sep; 51(17):4544-8. PubMed ID: 1873798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
